Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ascendis Pharma A/s.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.039 Thank you for standing by and welcome to the Ascendance Pharma 4th Quarter 2025 00:00:05.039 -- 00:00:09.606 Earnings Conference Call. At this time, all participants are in listen-only mode. 00:00:09.606 -- 00:00:12.932 After the speaker's presentation, there will be a question and answer session. 00:00:12.932 -- 00:00:17.760 To ask a question during this session, you'll need to press star 1-1 on your telephone. 00:00:17.760 -- 00:00:21.005 If your question has been answered and you'd like to remove yourself from the queue, 00:00:21.005 -- 00:00:26.744 simply press star 1-1 again. We ask that you please limit yourself to one question. 00:00:26.744 -- 00:00:29.407 As a reminder, today's program is being recorded. 00:00:29.407 -- 00:00:34.412 And now I'd like to introduce your host for today's program, Chad Fugere, Vice 00:00:34.412 -- 00:00:35.793 President, Investor Relations. 00:00:35.793 -- 00:00:40.318 Please go ahead, sir. Thank you, operator, and thank you, everyone, for joining our full 00:00:40.318 -- 00:00:43.861 year 2025 financial results conference call. 00:00:43.861 -- 00:00:48.185 I'm Chad Fugere, Vice President, Investor Relations at Ascendus Pharma. 00:00:48.185 -- 00:00:52.710 Joining me on the call today are Yen Mickelson, President and Chief Executive Officer, 00:00:52.710 -- 00:00:58.085 Scott Smith, Chief Financial Officer, Sherry Glass, Chief Business Officer, 00:00:58.085 -- 00:01:03.232 Jay Wu, Executive Vice President and President Ascendus U.S., 00:01:03.232 -- 00:01:08.399 and Amy Hsu, Chief Medical Officer. Before we begin, I'd like to remind you 00:01:08.399 -- 00:01:11.864 that this conference call will contain forward-looking statements that are intended to 00:01:11.864 -- 00:01:16.310 be covered under...